Bristol-Myers Squibb is planning to buy Celgene for $74 billion. Celgene’s pipeline of cancer drugs would bolster BMS’ portfolio, and Celgene is also developing a CAR-T cell therapy that could compete with treatments from Novartis and Gilead Sciences. The deal is expected to close in Q3. (CNBC)

MDC Partners has named an executive committee to lead the company, according to an SEC filing. The board is in charge of finding a replacement for former CEO Scott Kauffman, who left his position on December 31. The holding company is also reportedly exploring a sale of its assets. (Adweek)

The White House has confirmed Kelvin Droegemeier as director of the Office of Science and Technology Policy. The position has been empty since President Donald Trump took office. James Carroll has also been confirmed as adviser of the Office of National Drug Control Policy. (STAT)

Takeda has created a cell therapy unit for immuno-oncology research. The drugmaker is working to develop CAR-T therapies for multiple myeloma, acute myeloid leukemia, and solid tumor cancers. Takeda is about to acquire Shire. (Endpoints)

ICR has acquired Westwicke Partners, effective January 2. ICR is combining its healthcare IR and PR practice with the healthcare financial communications agency. The price of the deal was not disclosed. The combined entity has been placed under the leadership of Westwicke founders Bob East and Mark Klausner, who are serving as managing partners. (MM&M)